Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) — Georgina V. Long (2019) | RDL Network
Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)
Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, Richard A. Scolyer, Louise Emmett, Grant A. McArthur, Alexander M. Menzies
Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Serigne Lo, Alexander Guminski, Michael P. Brown, M. M. González, Katrina Diamante, Shahneen Sandhu, Richard A. Scolyer, Louise Emmett, Grant A. McArthur
Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Tracy T.Y.E. Liaw, Maria Gonzalez, Jill Davison, Elizabeth Paton, Richard A. Scolyer, Louise Emmett, Grant A. McArthur
Anthony B. El-Khoueiry, Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho Yeong Lim, Arteid Memaj, Ashwin R. Sama, Chiun Hsu
Georgina V. Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander Guminski, Michael P. Brown, James S. Wilmott, Jarem Edwards, Maria Gonzalez, Richard A. Scolyer, Alexander M. Menzies, Grant A. McArthur
Discussion(0)
No comments yet. Be the first to comment.